<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>Agomelatine</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>Agomelatine</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/thumb/9/9f/Agomelatine_formula.svg/250px-Agomelatine_formula.svg.png"/></li>
<li>Pharmacological Actions</li>
<li>Agomelatine's mechanism of action involves dual receptor interactions, which are critical to its therapeutic effects. It acts as a potent agonist at melatonin MT1 and MT2 receptors and as an antagonist at serotonin 5-HT2C receptors, with some affinity for 5-HT2B receptors, though the clinical relevance of the latter is less established.</li>
<ul>
<li>Melatonin MT1 Receptor Agonism: Agomelatine binds with high affinity to MT1 receptors, with a Ki value of approximately 0.1 nM. This agonism is believed to regulate circadian rhythms, promoting sleep onset and improving sleep quality, particularly by attenuating alerting signals to the cortex.</li>
<li>Melatonin MT2 Receptor Agonism: Similarly, it has a Ki of about 0.12 nM for MT2 receptors, contributing to phase-shifting circadian rhythms, which is beneficial for patients with disrupted sleep-wake cycles. This action is thought to advance the timing of sleep and body temperature decline.</li>
<li>Serotonin 5-HT2C Receptor Antagonism: With a Ki of approximately 631 nM, agomelatine acts as a neutral antagonist at 5-HT2C receptors, leading to increased release of norepinephrine and dopamine in the frontal cortex. This disinhibition is thought to enhance mood and cognitive function, a key aspect of its antidepressant effect.</li>
<li>Serotonin 5-HT2B Receptor Antagonism: It also interacts with 5-HT2B receptors, with a Ki of about 660 nM, but the functional significance is less clear, with limited evidence on its contribution to therapeutic outcomes.</li>
</ul>
<li>These actions influence over time in a biphasic manner. Acute effects, particularly on sleep and circadian rhythms, are observed shortly after administration, often within hours to days, due to its rapid absorption and receptor interactions. For instance, studies have shown improvements in sleep onset and quality from the first week of treatment, likely due to MT1/MT2 agonism. Chronic effects, such as antidepressant efficacy, develop over weeks, with clinical trials indicating significant mood improvements after 6-8 weeks, mediated by the combined melatonergic and serotonergic effects.</li>
<li>Pharmacokinetic Profile</li>
<li>Agomelatine's pharmacokinetics are characterized by rapid absorption and metabolism, with significant implications for its clinical use:</li>
<ul>
<li>Half-life: The mean plasma half-life is between 1 and 2 hours, indicating rapid elimination, which aligns with its once-daily dosing at bedtime to mimic natural melatonin rhythms.</li>
<li>Bioavailability: Oral bioavailability is less than 5% at therapeutic doses, attributed to extensive first-pass hepatic metabolism, with substantial interindividual variability. This low bioavailability is higher in women and increased by oral contraceptives, while smoking reduces it.</li>
<li>Absorption and Distribution: It is rapidly absorbed, with peak plasma concentrations reached within 1 to 2 hours. The volume of distribution is about 35 L, and it is 95% bound to plasma proteins, with no significant changes in binding with age or renal impairment, though free fraction doubles in hepatic impairment.</li>
<li>Metabolism and Excretion: Metabolized mainly via CYP1A2 (90%), with minor contributions from CYP2C9 and CYP2C19, producing inactive metabolites that are rapidly conjugated and excreted, primarily in urine (80%), with negligible unchanged drug.</li>
</ul>
<li>Dosage and Safety Considerations</li>
<ul>
<li>Standard Dosage: The recommended starting dose is 25 mg once daily at bedtime, taken orally with or without food. This dose is effective for many patients, as evidenced by clinical trials showing significant antidepressant effects at this level.</li>
<li>Dose Adjustment: If there is no improvement after two weeks, the dose may be increased to 50 mg once daily, based on individual benefit/risk assessment and strict liver function monitoring. Treatment duration should be at least 6 months to ensure symptom-free status.</li>
<li>Safe Range and Minimum Effective Dose: The safe range is 25-50 mg daily, with 25 mg identified as the minimum effective dose from studies comparing doses of 1, 5, and 25 mg, where 25 mg showed the best effectiveness.</li>
<li>Maximum Recommended Dose: 50 mg daily is the maximum recommended dose, with higher doses not advised due to increased risk of liver enzyme elevations.</li>
<li>Overdose and Toxicity: In overdose cases, doses up to 7.5 g have been reported, primarily causing drowsiness, dizziness, and nausea in sole ingestions, with no severe toxicity. Polydrug overdoses showed more severe effects, but these were likely due to co-ingested substances. Liver transaminase rises, a known risk at therapeutic doses, were not reported in overdose scenarios, suggesting a wide safety margin.</li>
<li>LD50: Specific LD50 values are not available in public sources, but animal studies and overdose data suggest it is likely high, given the lack of severe toxicity even at high doses in humans.</li>
<li>When It Becomes Too Dangerous: Doses above 50 mg may increase the risk of adverse effects, particularly liver enzyme elevations, with monitoring recommended. The exact threshold for danger is unclear, but clinical guidelines contraindicate use in hepatic impairment and advise caution above recommended doses.</li>
</ul>
<li>Clinical Implications and Research Gaps</li>
<li>Agomelatine's dual action offers benefits for both sleep and mood, with acute effects on sleep architecture observed in polysomnography studies, showing increased slow-wave sleep and improved efficiency. However, research gaps remain, particularly in precise functional EC50 values for MT1/MT2 agonism and long-term safety at higher doses. The controversy around its efficacy, as noted in some reviews, highlights the need for further studies, especially in diverse populations.</li>
<li>In conclusion, agomelatine presents a novel therapeutic option with a favorable safety profile within recommended doses, but careful monitoring for liver function is essential. Its pharmacological actions and pharmacokinetic properties underpin its clinical utility, with ongoing research needed to fully elucidate its safety at higher doses and in special populations.</li>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main><script src="../js/router.js"></script></body></html>